Akatinol Memantine, 20 mg 98 pcs

Pharmacodynamics

As a non-competitive antagonist of N-methyl-D-aspartate (NMDA)-receptors it has modulatory effect on glutamatergic system. It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics

Akatinol Memantine is quickly and completely absorbed after oral administration. Maximum plasma concentration is reached within 2-6 hours. No cumulation of the drug is noted in normal renal function. Excretion is biphasic. Period of semiejection half-life is 4-9 hours in the first phase, and 40-65 hours in the second phase.
It is excreted in the urine.

Indications

Dementia of Alzheimer’s type, vascular dementia, mixed dementia of all degrees of severity.

Pharmacological effect

Pharmacodynamics

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics

After oral administration, Akatinol Memantine is quickly and completely absorbed. The maximum concentration in blood plasma is achieved within 2-6 hours. With normal renal function, no accumulation of the drug was observed. Excretion occurs in two phases. The half-life is 4-9 hours in the first phase, 40-65 hours in the second phase.
Excreted in urine.

Special instructions

The optimal dose is achieved gradually, with the dose increasing every week.

Active ingredient

Memantine

Composition

Active ingredient:

memantine hydrochloride 20 mg;

Excipients:

lactose,

MCC,

colloidal silicon dioxide,

talc,

magnesium stearate,

Shell:

methacrylic acid copolymer,

sodium lauryl sulfate,

talc.

Contraindications

individual hypersensitivity to the drug Akatinol Memantine;
severe renal dysfunction;
pregnancy;
breast-feeding;
children under 18 years of age (due to insufficient data).

With caution:

thyrotoxicosis;
epilepsy;
convulsions (including history);
myocardial infarction;
heart failure.

Side Effects

Adverse reactions are classified according to clinical manifestations (according to damage to certain organ systems) and frequency of occurrence:

From the body as a whole – common adverse reactions
Often
Headache
Rarely
Fatigue
Infections
Rarely
Fungal infections
Mental disorders
Often
Drowsiness
Rarely
Confusion
Rarely
Hallucinations1
Frequency not set
Psychotic reactions2
Cardiovascular disorders
Rarely
Hypertension
Rarely
Venous thrombosis/thromboembolism
Gastrointestinal disorders
Often
Constipation
Rarely
Nausea, vomiting
Frequency not set
Pancreatitis2
Disorders of the central and peripheral nervous system
Often
Dizziness
Rarely
Gait disturbance
Very rarely
Convulsions

1Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

2 There are isolated reports of the occurrence of these adverse reactions when using the drug in clinical practice (data obtained after the drug went on sale).

Interaction

When used simultaneously with barbiturates, neuroleptics, and anticholinergics, the effect of the latter may be enhanced. When used together, it may change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be selected individually.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

4 years

Manufacturer

Rottendorf Pharma GmbH, Germany